Integrating nitrosamine theoretical formation into Translational Pharmaceutics: Mitigating risks during accelerated...

Area of Science:

• Pharmaceutical Development
• Regulatory Science
• Drug Safety

Background:

• Nitrosamine impurities pose significant carcinogenic risks in pharmaceuticals.
• Regulatory bodies (ICH M7) classify nitrosamines as a
• cohort of concern
• (CoC), requiring strict control and risk assessment.
• Recent guidance extends nitrosamine control expectations to early-phase clinical development.

Purpose of the Study:

• To introduce a novel approach for managing nitrosamine risk during pharmaceutical development.
• To leverage Translational Pharmaceutics and formulation design spaces for real-time risk control.
• To streamline regulatory compliance and maintain formulation flexibility.

Main Methods:

• Utilizing Translational Pharmaceutics to integrate formulation development, GMP manufacturing, and clinical testing.
• Implementing a formulation design space for prospective formulation optimization.
• Embedding nitrosamine risk assessment within the formulation design space.

Main Results:

• Real-time, evidence-based control of nitrosamine risk during formulation development.
• A single, adaptive nitrosamine risk assessment strategy for multiple clinical formulation variants.
• Avoidance of multiple regulatory amendments common in sequential development.

Conclusions:

• Embedding nitrosamine risk assessment within a formulation design space offers a key operational advantage.
• This integrated approach facilitates real-time control and simplifies regulatory oversight.
• It enables flexible formulation development while ensuring patient safety.